UniQure gets an FDA decision date; Teva scraps brain drug study

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 03 Nov, 13:41 UTC

The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.

sciencesecurity

Sources

• T2UniQure gets an FDA decision date; Teva scraps brain drug studyBioPharma Dive / Healthcare Dive / MedTech Dive03 Nov, 13:41